HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 36, 32453-32458, September 6, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/36/32453    most recent M111245200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeshita, A. Articles by Ozawa, Y. Search for Related Content PubMed PubMed Citation Articles by Takeshita, A. Articles by Ozawa, Y. Social Bookmarking                      What's this?

Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of CYP3A4 Inhibition by Xenobiotics^*

Akira Takeshita, Manabu Taguchi, Noriyuki Koibuchi^§, and Yasunori Ozawa

From the Division of Endocrinology and Metabolism, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo 105-8470, Japan and the ^§ Department of Physiology, Gunma University School of Medicine and Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation, Maebashi, Gunma 371-8511, Japan

Received for publication, November 26, 2001, and in revised form, June 3, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cytochrome P450 monooxygenase 3A4 (CYP3A4) is responsible for the metabolism of endogenous steroids and drugs in liver. Many inducers of human CYP3A4, such as rifampicin, bind to the orphan nuclear receptor SXR (steroid and xenobiotic receptor) as ligands and stimulate transcription on xenobiotic response elements located in the CYP3A4 promoter. Conversely, it is not known whether SXR mediates the transcriptional repression. We thus examined transcriptional repression of SXR and its interaction with corepressors, NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) using reporter assays in the absence and presence of ligand. Cotransfection of SMRT, but not NCoR, inhibited not only basal but also rifampicin-induced transcriptional activity of SXR on the CYP3A4 promoter through specific SMRT-SXR interaction in HepG2 cells. Interestingly, rifampicin also increased the interaction of SXR with SMRT as well as with coactivator SRC-1. On the other hand, the anti-fungal agent ketoconazole decreased SXR interaction with both SRC-1 and SMRT. Ketoconazole partially inhibited corticosterone-induced SXR-mediated transcription on the CYP3A4 promoter. Taken together, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription. Further, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at the transcriptional level.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The cytochromes P450 (CYPs)¹ superfamily consists of heme-containing monooxygenases that play an important role in the oxidative metabolism of endogenous substances, natural compounds, and xenobiotics. The CYP3A4 gene product is the most abundant CYP that is expressed in human liver and is involved in the metabolism of drugs, steroids, and environmental procarcinogens (reviewed in Ref. 1). The expression of the CYP3A4 is transcriptionally activated by many natural and xenobiotic compounds. This induction of the CYP3A4 gene by xenobiotic compounds, in turn, can cause drug-drug interactions. One such example is the antibiotic rifampicin, a well known inducer of the human CYP3A4 gene, which then increases the clearance of immunosuppressant cyclosporine A, oral contraceptives, glucocorticoid derivatives, and calcium channel blockers. Recently, the orphan nuclear receptor, steroid and xenobiotic receptor (SXR) (also called pregnane X receptor (PXR)), has been isolated (2-5). SXR is highly expressed in the liver and small intestine and regulates the CYP3A4 gene. SXR forms heterodimer with retinoid X receptor (RXR) on xenobiotic-response elements (XREs), located in the promoter region of the CYP3A4 gene. A variety of known CYP3A4 inducers such as rifampicin, clotrimazole, and nifedipine bind to SXR as ligands and stimulate transcription of the CYP3A4 (3-6).

Ligand-dependent interaction with coactivators activates transcription, and ligand-independent interaction with corepressors represses basal transcription by certain nuclear receptors such as thyroid hormone receptors (TRs) and retinoic acid receptors (RARs) (7, 8). Recent studies revealed that the various inducers of the CYP3A4 recruit the nuclear receptor coactivators such as steroid receptor coactivator-1 (SRC-1) to the ligand-binding domain (LBD) of SXR (2, 3, 9, 10). However, it is not known whether SXR represses basal transcription. NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid receptors) mediate basal repression by unliganded nuclear hormone receptors (11, 12). In the present study, we analyzed the silencing ability of SXR and its interaction with the corepressors (NCoR and SMRT) in CYP3A4 gene regulation.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Reagents and Chemicals-- Rifampicin, corticosterone, and triiodothyronine (T₃) were obtained from Sigma. Ketoconazole was kindly provided by Janssen Research Foundation (Beerse, Belgium). Troglitazone was kindly provided by Sankyo Co. Ltd. (Tokyo, Japan).

Plasmids-- Human SXR in pCDG1 was kindly provided by Dr. R. M. Evans, the Salk Institute, La Jolla, CA (4). Mouse NCoR in pCEP4 (Invitrogen) and human SMRT in pCMX were described previously (13). A schematic diagram of the GAL4 or VP16 fusion constructs used is shown in Fig. 1. GAL4 SXR-LBD and GAL4 SRC-1-RID were constructed by ligating the LBD of human SXR (amino acids 107-434) (10) and nuclear receptor-interacting domain (RID) containing three LXXLL motifs in human SRC-1 (amino acids 595-780) (14) into the pM expression vector (CLONTECH, Palo Alto, CA), respectively. VP16 SXR-LBD and VP16 SRC-1-RID were constructed by ligating the same amino acid fragments of SXR and SRC-1 in GAL4 SXR-LBD and GAL4 SRC-1-RID downstream of the VP16 activation domain in AASV-VP16 (kindly provided by Dr. S. M. Weissman, Yale University School of Medicine, New Haven, CT) (15), respectively. GAL4 NCoR-RID, GAL4 SMRT-RID, VP16 NCoR-RID, and VP16 SMRT-RID containing receptor-interacting motifs, (I/L)XXII, were kindly provided by Dr. A. N. Hollenberg, (Deaconess Medical Center, Boston, MA) (16, 17).

View larger version (17K): [in this window] [in a new window]   Fig. 1.   Schematic diagram of GAL4 or VP16 constructs used in transfection reporter assays. GAL4 SXR-LBD and VP16 SXR-LBD contain residues 107-434 of human SXR. GAL4 NCoR-RID and VP16 NCoR-RID contain residues 1579-2454 of human NCoR. The fragment of NCoR contains three consensus (I/L)XXII motifs (CoRNR boxes), which are important for interaction with nuclear hormone receptors. GAL4 SMRT-RID and VP16 SMRT-RID contain the homologous region of the NCoR fragment (residues 1669-2507 of human SMRT). The fragment of SMRT contains two consensus (I/L)XXII motifs. GAL4 SRC-1-RID and VP16 SRC-1-RID contain residues 595-780 of human SRC-1. The fragment of SRC-1 contains three consensus LXXLL motifs, which are important for ligand-dependent interaction with nuclear hormone receptors. bHLH, basic helix-loop-helix; PAS, Per-Arnt-Sim; CBP, CREB (cAMP-response element-binding protein)-binding protein.

The chimeric CYP3A4 luciferase (LUC) reporter construct, a xenobiotic-responsive enhancer module (XREM)-CYP3A4-LUC containing the enhancer (nucleotides 7836 to 7208) and promoter (nucleotides 362 to +53) of human CYP3A4 driving luciferase expression, was kindly provided by Dr. S. A. Kliewer, GlaxoSmithKline, Research Triangle Park, NC (18, 19). Another LUC reporter construct, 5× upstream activating sequence (UAS)-thymidine kinase minimum promoter (TK)-LUC, was kindly provided by Dr. A. N. Hollenberg (16).

Transient Cotransfection Experiments-- HepG2 cells or CV-1 cells were grown in Dulbecco's modified Eagle's medium, 5% fetal calf serum. The serum was stripped of hormones by constant mixing with 5% (w/v) AG1-X8 resin (Bio-Rad) and powdered charcoal before ultrafiltration. The cells were maintained without antibiotics. Cells were transiently transfected using the calcium phosphate coprecipitation method in six-well plates with 1.5 µg of reporter plasmid containing the XREM-CYP3A4-LUC or 5× UAS-TK-LUC cDNA with expression vectors as indicated in the figure legends. CMV--galactosidase plasmid was used as an internal control. In some samples, empty expression vectors were added to equalize total transfected plasmid concentration. Cells were grown for 24 h in the absence or presence of ligands and then harvested. Cell extracts were analyzed for both luciferase and -galactosidase activity to correct for transfection efficiency as described previously (10). The corrected luciferase activities of untreated samples were normalized to the luciferase activities of samples as described in the figure legends. All transfection studies were repeated at least twice in triplicate. The results shown are the mean ± S.D.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

To determine the silencing ability of SXR and its interaction with the corepressors (NCoR and SMRT) on the CYP3A4 gene, transient transfection assays were performed. Human SXR expression plasmid and a reporter plasmid, XREM-CYP3A4-LUC, containing the enhancer and promoter of the CYP3A4 driving luciferase gene expression (18, 19) were cotransfected into a human liver-derived cell line, HepG2. Previously, it has been reported that CYP3A4 expression is induced by rifampicin in cultured HepG2 cells (20). We then examined SXR regulation of CYP3A4 gene expression in the absence or presence of rifampicin. As shown in Fig. 2, SXR showed a weak basal activation (2.3-fold) rather than repression in the absence of ligand. Rifampicin treatment stimulated SXR-mediated transcription by ~100-fold. Cotransfection of NCoR did not show a significant change in SXR transcription. However, cotransfection of SMRT repressed not only basal but also rifampicin-induced transcriptional activity of SXR. This result suggests that SMRT, but not NCoR, may be involved in SXR-mediated gene repression both in the absence and presence of ligands.

View larger version (14K): [in this window] [in a new window]   Fig. 2.   SMRT suppresses SXR-mediated transcription on the CYP3A4 promoter. The expression plasmid encoding human SXR (0.1 µg) and either mouse NCoR or human SMRT was cotransfected with the reporter plasmid XREM-CYP3A4-LUC (1.5 µg) and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with 10 µM rifampicin for 24 h and analyzed for luciferase activity. Luciferase activity was normalized to -galactosidase activity and then calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with vector alone in the absence of the ligand. The results are expressed as the mean ± S.D. (n = 3).

We then generated a series of fragments of SXR, fused to the DNA-binding domain (DBD) of the yeast transcription factor GAL4, to test their transcriptional activity on five copies of a GAL4 upstream activation sequence reporter (5× UAS- TK-LUC) in HepG2 cells (Fig. 3). The GAL4 SXR-LBD (amino acids 107-434) showed basal repression and rifampicin-induced transactivation. Of note, the GAL4 SXR-LBD contains the CoR box, located in the hinge region of SXR. The CoR box in TRs and RARs is one of the important binding sites for corepressor proteins such as NCoR and SMRT (11, 12). In addition to the repression function in the unliganded SXR-LBD, we observed another repression domain in the DBD of SXR (amino acids 41-107). The two GAL4 constructs that contain both DBD and LBD (amino acids 1-434 and 41-434) have less rifampicin-induced transcriptional activity than the GAL4 SXR-LBD (amino acids 107-434) (Fig. 3).

View larger version (17K): [in this window] [in a new window]   Fig. 3.   Transcriptional activation of GAL4 SXR fusion fragments. Schematic diagrams of GAL4 SXR fragments used are shown on the left. The GAL4 fusion constructs (0.1 µg) were cotransfected with 5× UAS-LUC (1.5 µg) and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with 10 µM rifampicin for 24 h and analyzed for luciferase activity. Luciferase activity was normalized to -galactosidase activity and then calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with GAL4 empty vector in the absence of the ligand. The results are expressed as the mean ± S.D. (n = 3).

Using a mammalian two-hybrid assay in HepG2 cells, we tested whether the silencing function of SXR-LBD is mediated by interaction with nuclear corepressors. The homologous regions of nuclear receptor-interacting domains in SMRT and NCoR were fused to the transactivation domain of VP16 (VP16 SMRT-RID and VP16 NCoR-RID in Fig. 1) (16, 17). As a control experiment, we used VP16 SRC-1-RID, which contains the nuclear receptor-interacting domain (10, 26). GAL4 and VP16 fusion constructs were cotransfected with a 5× UAS-TK-LUC reporter plasmid. As shown in Fig. 4, when GAL4 SXR-LBD was used, VP16 SRC-1-RID increased transcriptional activity in the presence of rifampicin, suggesting rifampicin-induced interaction of SXR with SRC-1 (10). Importantly, whereas cotransfection of VP16 NCoR-RID did not show significant change in GAL4 SXR-LBD-mediated transcription, cotransfection of VP16 SMRT-RID increased basal transcription in the absence of rifampicin. Transcription of GAL4 SXR-LBD also was significantly increased by cotransfection of VP16 SMRT-RID in the presence of rifampicin. Taken together, the data show that not only basal but also rifampicin-induced transcriptional activity of SXR was suppressed by SMRT (Fig. 2) and is likely due to interaction with SMRT in the absence or presence of rifampicin in HepG2 cells. Of note, rifampicin-induced activation of GAL4 SXR-LBD with VP16 alone in Fig. 4 is less than that of GAL4 SXR-LBD in Fig. 3, which is probably due to different amounts of total transfected DNA, GAL4 SXR-LBD, and reporter DNA used with the two studies. When GAL4 empty vector was used, no VP16 construct (VP16 SMRT-RID, VP16 NCoR-RID, or VP16 SRC-1-RID) increased the luciferase activity (data not shown).

View larger version (14K): [in this window] [in a new window]   Fig. 4.   In vivo interaction of SXR-LBD with coactivator (SRC-1) or corepressors (NCoR and SMRT). The expression plasmids encoding GAL4 SXR-LBD (0.1 µg) and VP16 alone, VP16 SRC-1-RID, VP16 NCoR-RID, or VP16 SMRT-RID (0.5 µg) were cotransfected with 5× UAS-TK-LUC reporter plasmid (1.5 µg) and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with 10 µM rifampicin for 24 h. The corrected luciferase activity was calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with GAL4 empty vector and VP16 empty vector in the absence of the ligand. The results are expressed as the mean ± S.D. (n = 3). The asterisk (*) denotes significant difference from the luciferase value of the column that represents GAL4 SXR-LBD and VP16 alone or GAL4 SXR-LBD and VP16 SMRT in the absence or presence of rifampicin (p < 0.05).

To examine the effect of rifampicin on SMRT-SXR interaction, the interactions between SXR and the two corepressors (NCoR and SMRT) were also examined using the reverse configuration of GAL4 or VP16 fusion constructs in HepG2 cells. The analysis of TR interaction with NCoR or SMRT was used as a control. As recently reported, NCoR, but not SMRT, specifically interacted with TR-LBD (16, 17). The addition of T₃ dissociated the TR and NCoR interaction (Fig. 5A). In contrast, SMRT, but not NCoR, interacted with SXR-LBD (Fig. 5B). Furthermore, rifampicin increased the interaction between SMRT and SXR-LBD. These mammalian two-hybrid assays suggest that the ligands of SXR may increase the interaction with both the coactivator, SRC-1, and the corepressor, SMRT. We also used CV-1 cells instead of HepG2 cells to test the specificity. In the absence of ligand, SMRT, but not NCoR, interacted with SXR-LBD in CV-1 cells. However, rifampicin treatment neither increased nor decreased the interaction of SXR with SMRT (data not shown). In addition, GST pull-down assays using ³⁵S-labeled SXR with GST SMRT-RID or GST NCoR-RID failed to show ligand-dependent interaction of SXR with both corepressors (data not shown). Therefore, ligand-dependent interaction of SXR with SMRT in HepG2 cells may require other cell-specific factor(s) or post-transcriptional modification.

View larger version (16K): [in this window] [in a new window]   Fig. 5.   In vivo interaction of corepressors with TR and SXR. The expression plasmids encoding GAL4 NCoR-RID or GAL4 SMRT-RID (0.1 µg) were cotransfected with 0.5 µg of VP16 TR-LBD (A) or VP16 SXR-LBD (B), 5× UAS-TK-LUC reporter plasmid (1.5 µg), and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with 1 µM T3 (A) or 10 µM rifampicin (B) for 24 h. The corrected luciferase activity was calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with GAL4 NCoR and VP16 alone or GAL4 SMRT and VP16 alone in the absence of the ligand. The results are expressed as the mean ± S.D. of the representative experiments (panel A and GAL4 NCoR experiment in panel B, n = 3) or triplicate sample in three separate experiments (GAL4 SMRT experiment in panel B, n = 9). The asterisk (*) denotes significant difference from the luciferase value of the column that represents GAL4 SMRT and VP16 alone or GAL4 SMRT and VP16 SXR-LBD in the absence or presence of rifampicin (p < 0.0001).

The induction of the CYP3A4 enzyme is mainly explained by the xenobiotic-induced transactivation of SXR. On the other hand, the inhibition of the CYP3A4 enzyme by xenobiotics, such as the drugs nefazodone, clarithromycin, erythromycin, itraconazole, and ketoconazole, is generally thought to be the inhibition of the enzyme activity at post-transcriptional level (1). Ketoconazole, an anti-fungal agent, is known as a strong inhibitor of CYP3A4. It inhibits the CYP3A4 action with low K_i value by forming a complex with the CYP3A4 enzyme (1, 21, 22). However, as shown in Fig. 6, ketoconazole partially inhibited corticosterone-induced SXR activation. Of note, ketoconazole treatment alone showed a weak agonistic activity (~8-fold). This result suggest that ketoconazole may act as an antagonist only when the SXR is activated by its agonist such as corticosterone.

View larger version (14K): [in this window] [in a new window]   Fig. 6.   Ketoconazole partially inhibits corticosterone-induced SXR transcription. The expression plasmid encoding SXR (0.1 µg) was cotransfected with reporter plasmid XREM-CYP3A4-LUC (1.5 µg) and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with different concentrations of corticosterone and/or ketoconazole for 24 h. The corrected luciferase activity was calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with the empty expression vector in the absence of the ligand. The results are expressed as the mean ± S.D. (n = 3).

To understand the mechanism of the antagonistic activity by ketoconazole, the effect of ketoconazole for the interaction of SXR with SMRT or SRC-1 was analyzed by a mammalian two-hybrid assay in HepG2 cells (Fig. 7). Constitutive interaction of SXR with SMRT or SRC-1 was enhanced by rifampicin or corticosterone treatment. On the other hand, ketoconazole dissociated the interaction of SXR with SMRT or SRC-1 to near basal level. Thus, ketoconazole may inhibit corticosterone-induced transactivation by disrupting SXR-coactivator interaction directly.

View larger version (17K): [in this window] [in a new window]   Fig. 7.   The effect of ketoconazole on the interaction of SXR with SMRT or SRC-1. The expression plasmids encoding GAL4 SMRT-RID (A) or GAL4 SRC1-RID (B) (0.1 µg) were cotransfected with VP16 SXR-LBD (0.5 µg), 5× UAS-TK-LUC reporter plasmid (1.5 µg), and CMV--galactosidase control vector (0.1 µg) in HepG2 cells. Cells were treated with 10 µM rifampicin, 10 µM corticosterone, or 5 µM ketoconazole for 24 h. The corrected luciferase activity was calculated as -fold luciferase activity with 1-fold basal activity defined as the luciferase activity with GAL4 SMRT and VP16 empty vector (A) or GAL4 SRC-1 and VP16 empty vector (B) in the absence of the ligand. The results are expressed as the mean ± S.D. (n = 3).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The nuclear hormone receptors (NRs) such as TRs and RARs repress gene transcription in the absence of ligands. The repression is mediated by the interaction of the NRs with nuclear corepressors such as NCoR and SMRT (7, 8, 11, 12). SXR belongs to the same subfamily of the NRs as TRs and RARs, which heterodimerize with RXRs and mediate ligand-dependent transcription. SXR regulates various members of the CYP enzymes including CYP3A4, CYP3A11, and CYP2C8 (24, 25). The basal level of the CYP3A11 mRNA was increased in the SXR null mouse, indicating that SXR may have a repression function in vivo (24). In the present study, we showed that unliganded SXR exhibited basal repression on the heterologous promoter. Two repression domains were located in the LBD and DBD of SXR. We found the repression function of the LBD-SXR was mediated by the specific interaction with SMRT. We have not analyzed how the DBD-SXR mediates repression. Similar to SXR, we reported previously that the DBD of TR contains an inhibitory region, which prevents full-length wild-type TR transcriptional activation in the GAL4 chimeric receptor system (26). Mathur et al. (27) reported a corepressor protein, PSF (polypyrimidine tract-binding protein-associated splicing factor), which binds to the DBD of type II nuclear hormone receptors such as TRs and RXRs. They showed that PSF interacts with Sin3A and mediates silencing through the recruitment of histone deacetylases. Importantly, although thyroid hormone (T₃) dissociates TR-NCoR interaction, the levels of TR-bound PSF and Sin3A remain unchanged (27). It will be interesting to test the interaction of DBD-SXR with PSF. When we used the CYP3A4 promoter, we failed to observe basal repression. However, cotransfection of SMRT, but not NCoR, inhibited the SXR transcription. We and others reported previously that conformational change(s) of NRs induced by the specific hormone-response elements may influence the nature of binding to coactivators such as SRC-1 (28, 29). In our mammalian two-hybrid assays, SXR showed constitutive interaction with both SRC-1 and SMRT. The relative balance of SXR interaction with coactivators and corepressors may determine the specific promoter activity. It also will be important to know whether the basal transcriptional activities by SXR depend on the specific XREs of the promoters.

We showed that SXR specifically interacts with SMRT, but not NCoR. While our work was in progress, Synold et al. (30) reported preferential recruitment of SMRT by SXR in CV-1 cells, consistent with our result. Although NCoR and SMRT share a similar structure in their C-terminal nuclear receptor-interacting domains, recent studies demonstrated that there is specificity in terms of NR recruitment of corepressors. TR1 preferentially interacts with NCoR, whereas RAR preferentially interacts with SMRT (16, 17). (I/L)XXII motifs and the adjacent  helical structure within the nuclear corepressor IDs are critical for mediating interactions with NRs (31, 32). NCoR contains three IDs, whereas SMRT has two IDs (17, 33). In vitro and in vivo interaction studies using fragments and chimeric mutants of IDs revealed that the preferences of TR and RAR interaction with the distinct corepressors are due to the sequence differences in the IDs (16, 17). Vitamin D receptor has also been reported to have preferred interaction with SMRT similar to SXR (34). It would be interesting to know which ID(s) of SMRT is important for the specific interaction with SXR.

In HepG2 cells, the SXR-SMRT interaction was unexpectedly increased by rifampicin or corticosterone treatment. In CV-1 cells, we failed to observe such ligand-dependent interaction of SXR with SMRT. Synold et al. (30) showed that the anti-cancer drug paclitaxel, but not docetaxel, disrupted the SXR-SMRT interaction, whereas both drugs induced SXR-SRC-1 interaction in CV-1 cells. Although we have not analyzed SXR-SMRT interaction using paclitaxel and docetaxel in HepG2 cells, the effect of xenobiotics on SXR-SMRT interaction may be different among different tissues. In fact, the agonist-induced recruitment of corepressors in the specific cell is not restricted to the SXR. Smith et al. (35) have reported that SMRT inhibits 4-hydroxytamoxifen agonist activity of estrogen receptor  in HepG2 cells.

The long QT syndrome is a group of disorders characterized by a prolonged QT interval, and this disorder promotes the specific type of life-threatening ventricular tachycardia, torsades de pointes. The long QT syndrome can be inherited or acquired as an adverse response to electrolyte abnormalities, bradycardia, or drugs that include ketoconazole, which inhibits CYP activities (1). Using human liver microsomes, Maurice et al. (21) reported that ketoconazole is a strong and selective inhibitor of the CYP3A4. It has been generally considered that imidazole derivatives such as ketoconazole are able to interact with various CYPs of liver microsomes, thereby inhibiting some monooxygenase activities (1). However, we showed that ketoconazole disrupted both SXR-SMRT and SXR-SRC-1 interactions and partially inhibited corticosterone-stimulated SXR transcription on the CYP3A4 promoter in HepG2 cells. Blumberg et al. (4) reported that the cocktails of endogenous steroids containing corticosterone additively increase human SXR-mediated transcription. Thus, it is possible that many endogenous steroid hormones in serum may additively stimulate SXR transcription in vivo. It has been reported that the plasma concentration of ketoconazole after 1 h of oral administration of a 200-mg single dose is 6.2 µg/ml (i.e. 11.7 µM) (36). Ketoconazole may inhibit the endogenous steroid-induced transcription in vivo to alter the CYP3A4 transcription.

In summary, our results suggest that the differential interaction of coactivators and corepressors induced by various xenobiotics may alter SXR-mediated transcription. Furthermore, the effects of ketoconazole on the CYP3A4 gene suppression may explain, in part, drug-induced inhibition of the CYP3A4 action at transcriptional level.

	ACKNOWLEDGEMENTS

We are grateful for critical review and polish of the manuscript by Dr. P. M. Yen (MCEB, NIDDK, National Institutes of Health, Bethesda, MD). We thank Drs. S. M. Weissman (Yale University School of Medicine, New Haven, CT), R. M. Evans (Salk Institute, La Jolla, CA), A. N. Hollenberg, and S. A. Kliewer (GlaxoSmithKline, Research Triangle Park, NC) for providing plasmids.

	FOOTNOTES

^* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Div. of Endocrinology and Metabolism, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato, Tokyo 105-8470, Japan; Tel.: 81-3-3588-1111; Fax: 81-3-3582-7068; E-mail: coactivator@mac.com.

Published, JBC Papers in Press, June 18, 2002, DOI 10.1074/jbc.M111245200

	ABBREVIATIONS

The abbreviations used are: CYP, cytochrome P450; CYP3A4, CYP monooxygenase 3A4; SXR, steroid and xenobiotic receptor; RXR, retinoid X receptor; XRE, xenobiotic-response element; XREM, xenobiotic-responsive enhancer module; CoR, corepressor; NCoR, nuclear receptor CoR; SMRT, silencing mediator for retinoid and thyroid receptors; TR, thyroid hormone receptor; RAR, retinoic acid receptor; NR, nuclear hormone receptor; LUC, luciferase; TK, thymidine kinase; UAS, upstream activating sequence; LBD, ligand-binding domain; ID, interacting domain; RID, receptor-interacting domain; DBD, DNA-binding domain; PSF, polypyrimidine tract-binding protein-associated splicing factor; T₃, triiodothyronine.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al. The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709. [Abstract] [Full Text] [PDF]

				H. Wang, H. Li, L. B. Moore, M. D. L. Johnson, J. M. Maglich, B. Goodwin, O. R. R. Ittoop, B. Wisely, K. Creech, D. J. Parks, et al. The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor Mol. Endocrinol., April 1, 2008; 22(4): 838 - 857. [Abstract] [Full Text] [PDF]

				C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507. [Abstract] [Full Text] [PDF]

				L. Svecova, R. Vrzal, L. Burysek, E. Anzenbacherova, L. Cerveny, J. Grim, F. Trejtnar, J. Kunes, M. Pour, F. Staud, et al. Azole Antimycotics Differentially Affect Rifampicin-Induced Pregnane X Receptor-Mediated CYP3A4 Gene Expression Drug Metab. Dispos., February 1, 2008; 36(2): 339 - 348. [Abstract] [Full Text] [PDF]

				S. Ekins, C. Chang, S. Mani, M. D. Krasowski, E. J. Reschly, M. Iyer, V. Kholodovych, N. Ai, W. J. Welsh, M. Sinz, et al. Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites Mol. Pharmacol., September 1, 2007; 72(3): 592 - 603. [Abstract] [Full Text] [PDF]

				D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF]

				A. Takeshita, K. Inagaki, J. Igarashi-Migitaka, Y. Ozawa, and N. Koibuchi The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J. Endocrinol., September 1, 2006; 190(3): 897 - 902. [Abstract] [Full Text] [PDF]

				C. Duret, M. Daujat-Chavanieu, J.-M. Pascussi, L. Pichard-Garcia, P. Balaguer, J.-M. Fabre, M.-J. Vilarem, P. Maurel, and S. Gerbal-Chaloin Ketoconazole and Miconazole Are Antagonists of the Human Glucocorticoid Receptor: Consequences on the Expression and Function of the Constitutive Androstane Receptor and the Pregnane X Receptor Mol. Pharmacol., July 1, 2006; 70(1): 329 - 339. [Abstract] [Full Text] [PDF]

				D. R. Johnson, C.-W. Li, L.-Y. Chen, J. C. Ghosh, and J. D. Chen Regulation and Binding of Pregnane X Receptor by Nuclear Receptor Corepressor Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT) Mol. Pharmacol., January 1, 2006; 69(1): 99 - 108. [Abstract] [Full Text] [PDF]

				S. Mani, H. Huang, S. Sundarababu, W. Liu, G. Kalpana, A. B. Smith, and S. B. Horwitz Activation of the Steroid and Xenobiotic Receptor (Human Pregnane X Receptor) by Nontaxane Microtubule-Stabilizing Agents Clin. Cancer Res., September 1, 2005; 11(17): 6359 - 6369. [Abstract] [Full Text] [PDF]

				Y. Lu, J.-M. Heydel, X. Li, S. Bratton, T. Lindblom, and A. Radominska-Pandya LITHOCHOLIC ACID DECREASES EXPRESSION OF UGT2B7 IN CACO-2 CELLS: A POTENTIAL ROLE FOR A NEGATIVE FARNESOID X RECEPTOR RESPONSE ELEMENT Drug Metab. Dispos., July 1, 2005; 33(7): 937 - 946. [Abstract] [Full Text] [PDF]

				T. Li and J. Y. L. Chiang Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7{alpha}-hydroxylase gene transcription Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G74 - G84. [Abstract] [Full Text] [PDF]

				T. Ikezoe, Y. Hisatake, T. Takeuchi, Y. Ohtsuki, Y. Yang, J. W. Said, H. Taguchi, and H. P. Koeffler HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4, Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo Cancer Res., October 15, 2004; 64(20): 7426 - 7431. [Abstract] [Full Text] [PDF]

				W. Miyazaki, T. Iwasaki, A. Takeshita, Y. Kuroda, and N. Koibuchi Polychlorinated Biphenyls Suppress Thyroid Hormone Receptor-mediated Transcription through a Novel Mechanism J. Biol. Chem., April 30, 2004; 279(18): 18195 - 18202. [Abstract] [Full Text] [PDF]

				C. Handschin and U. A. Meyer Induction of Drug Metabolism: The Role of Nuclear Receptors Pharmacol. Rev., December 1, 2003; 55(4): 649 - 673. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 277/36/32453    most recent M111245200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeshita, A. Articles by Ozawa, Y. Search for Related Content PubMed PubMed Citation Articles by Takeshita, A. Articles by Ozawa, Y. Social Bookmarking                      What's this?